NKGN 8-K 2026-09-02

NKGen Biotech, Inc. (NKGN) 8-K dated 2026-09-02 — accession 0001213900-26-096778.

NKGen Biotech, Inc. (NKGN) is a biotechnology company listed on US.

NKGen Biotech, Inc. filed a 8-K on 2026-09-02. Accession 0001213900-26-096778.

This 8-K covers: Material agreement (Item 1.01), New debt obligation (Item 2.03), Unregistered share sale (Item 3.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported NKGN revenue for 2023-12-31 was $0. Net income was -$83.0M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. NKGN currently screens at market cap $22.4M.

Not investment advice. The NKGN SEC hub lists recent forms. The stock page is the research view.